Startups
Rebrain
Pessac, France · Cambridge, Massachusetts, United States
RebrAIn is a French medical-software company developing supervised AI-based, patient-specific MRI processing and brain-targeting tools for functional neurosurgery. Its legal issuer is Rebrain SAS, SIREN892511866, active since January1,2021 according to the French government register; its US operating affiliate Rebrain US Corp is identified separately on the same corporate website. Neurosurgeon Emmanuel Cuny and Inria applied-mathematics researcher Nejib Zemzemi co-founded the University Hospital of Bordeaux/Inria spin-off following academic research. Its OptimMRI software processes preoperative DICOM MRI images and helps qualified clinicians visualize and localize anatomical structures, including STN/VIM, alongside other clinical methods for neurosurgical planning. FDA records confirm ClassII 510(k) clearance K230150 on July21,2023 and OptimMRI(v2) K242054 on August12,2024; these are software device clearances, not drug approvals, autonomous treatment authorization or independent proof of clinical benefit. The company also reports European CE marking, with an independently retrieved CE certificate not available in this audit. Its current public directory identifies David Caumartin as CEO, Emmanuel Cuny as CMO/board president and Nejib Zemzemi as CSO/CTO, a strategic board and nine scientific/medical advisers. The statutory register separately identifies David Caumartin as Président de SAS and Cuny/Zemzemi as Directeurs Généraux. Additional people in its January2025 team announcement are recorded as dated affiliations where current operating titles cannot be confirmed. A completed EUR3.7M seed financing announced March18,2024 was led by Karista, joined by NACO and unnamed existing investors. Karista’s portfolio year2023 is not treated as a second priced cash event. Regional/EU programme support is reported without an invented amount or paid-cash grant; a171K technology-transfer maturation budget is not assumed paid to this legal company. Executive-career logos are not treated as investors.
Founded 2021
Team
 Amine BenmoussaStrategic Board Member |
Anasse LaafouPublished team affiliation (January2025) |
Antoine d’HumièresPublished team affiliation (January2025) |
Antoine MorenoPublished team affiliation (January2025) |
 Ausaf A. BariScientific / Medical Advisory Board Member |
 Benoit ThiedeyStrategic Board Member |
 Charles MunyonScientific / Medical Advisory Board Member |
 David CaumartinChief Executive Officer · Strategic Board Member · Président de SAS (registered statutory officer) |
Dorothee UrietPublished team affiliation (January2025) |
Eléa RobertPublished team affiliation (January2025) |
 Emmanuel CunyCo-founder, Chief Medical Officer and Board President · Co-founder · Strategic Board Member · Directeur Général (registered statutory officer) |
 Jean RégisScientific / Medical Advisory Board Member |
 John RolstonScientific / Medical Advisory Board Member |
 Joohi Jimenez-ShahedScientific / Medical Advisory Board Member |
Kirushini SatkunaseelanPublished team affiliation (January2025) |
 Lain Hermes GonzálezScientific / Medical Advisory Board Member |
Lilou MarchandPublished team affiliation (January2025) |
Louise-Amélie SchmittPublished team affiliation (January2025) |
Martin DominguezPublished team affiliation (January2025) |
Matt SuminskiPublished team affiliation (January2025) |
 Michael J. KinsmanScientific / Medical Advisory Board Member |
Mohamed Aziz OmriPublished team affiliation (January2025) |
Narimane GassaPublished team affiliation (January2025) |
 Nejib ZemzemiCo-founder, Chief Scientific Officer and Chief Technology Officer · Co-founder · Strategic Board Member · Directeur Général (registered statutory officer) |
Paolo Joaquim dos SantosPublished team affiliation (January2025) |
Pauline MigerditichanPublished team affiliation (January2025) |
 Rees CosgroveScientific / Medical Advisory Board Member |
Robert LawPublished team affiliation (January2025) |
 Shayan MoosaScientific / Medical Advisory Board Member |
Thomas QueucheQuality and Regulatory Affairs Manager (FDA submission2024) · Data Protection Officer (published privacy policy) |
 Tom BeauvironnetStrategic Board Observer |